Bardwell PD et al (2004) Altered somatic hypermutation and reduced class-switch recombination in exonuclease 1–mutant mice. Nat Immunol 5:224–229

Article  CAS  PubMed  Google Scholar 

Cai Z, Ang X, Xu Z, Li S, Zhang J, Pei C, Zhou F (2021) A pan-cancer study of PD-1 and CTLA-4 as therapeutic targets. Trans Cancer Res 10:3993–4001

Cassetta L, Kitamura T (2018) Macrophage targeting: opening new possibilities for cancer immunotherapy. Immunology 155:285–293

Cotta-Ramusino C et al (2005) Exo1 Processes Stalled Replication Forks and Counteracts Fork Reversal in Checkpoint-Defective Cells. Mol Cell 17:153–159

Article  CAS  PubMed  Google Scholar 

Dougan M, Luoma AM, Dougan SK, Wucherpfennig KW (2021) Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell 184:1575–1588

Dzantiev L et al (2004) A Defined Human System That Supports Bidirectional Mismatch-Provoked Excision. Mol Cell 15:31–41

Article  CAS  PubMed  Google Scholar 

Fadaka A et al (2017) Biology of glucose metabolization in cancer cells. Journal of Oncological Sciences 3:45–51

Article  Google Scholar 

Giannattasio M et al (2010) Exo1 Competes with Repair Synthesis, Converts NER Intermediates to Long ssDNA Gaps, and Promotes Checkpoint Activation. Mol Cell 40:50–62

Article  CAS  PubMed  Google Scholar 

Gupta S, Shukla S (2022) Limitations of Immunotherapy in Cancer. Cureus 14:e30856 

Hamilton PT, Anholt BR, Nelson BH (2022) Tumour immunotherapy: lessons from predator–prey theory. Nat Rev Immunol 22:765–775

He D et al (2023) Multi-omics analysis reveals a molecular landscape of the early recurrence and early metastasis in pan-cancer. Front Genet 14:1061364

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lewis LK, Karthikeyan G, Westmoreland JW, Resnick MA (2002) Differential Suppression of DNA Repair Deficiencies of Yeast rad50, mre11 and xrs2 Mutants by EXO1 and TLC1 (the RNA Component of Telomerase). Genetics 160:49–62

Li H-X, Wang  S-Q, Lian Z-X, Deng S-L, Yu k (2022) Relationship between Tumor Infiltrating Immune Cells and Tumor Metastasis and Its Prognostic Value in Cancer. Cells 12:64

Liu J, Zhang J (2021) Elevated EXO1 expression is associated with breast carcinogenesis and poor prognosis. Ann Transl Med 9:135–135

Lv J, Shim JS (2015) Existing drugs and their application in drug discovery targeting cancer stem cells. Arch Pharm Res 38:1617–1626

Ma J et al (2022) Exonuclease 1 is a Potential Diagnostic and Prognostic Biomarker in Hepatocellular Carcinoma. Front Mol Biosci 9:889414

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marin-Acevedo JA et al (2018) Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol 11:39

Article  PubMed  PubMed Central  Google Scholar 

Morris EC, Neelapu SS, Giavridis T, Sadelain M (2022) Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 22:85–96

Postow MA, Callahan MK, Wolchok JD (2015) Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol 33:1974–1982

Rotte A (2019) Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res 38:255

Article  PubMed  PubMed Central  Google Scholar 

Schaetzlein S et al (2007) Exonuclease-1 Deletion Impairs DNA Damage Signaling and Prolongs Lifespan of Telomere-Dysfunctional Mice. Cell 130:863–877

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tishkoff DX, Boerger AL, Bertrand P, Filosi N, Gaida GM, Kane MF, Kolodner RD (1997) Identification and characterization of Saccharomyces cerevisiae EXO1, a gene encoding an exonuclease that interacts with MSH2. Proc Natl Acad Sci U S A 94:7487-7492

Tomimatsu N et al (2012) Exo1 plays a major role in DNA end resection in humans and influences double-strand break repair and damage signaling decisions. DNA Repair 11:441–448

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei K et al (2003) Inactivation of Exonuclease 1 in mice results in DNA mismatch repair defects, increased cancer susceptibility, and male and female sterility. Genes Dev 17:603–614

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wojtukiewicz MZ et al (2021) Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev 40:949–982

Article  PubMed  PubMed Central  Google Scholar 

Wu S, Zhu W, Thompson P, Hannun YA (2018) Evaluating intrinsic and non-intrinsic cancer risk factors. Nat Commun 9:3490

Xue C et al (2022) Role of main RNA modifications in cancer: N6-methyladenosine, 5-methylcytosine, and pseudouridine. Signal Transduct Target Ther 7:142

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang L et al (2024) Emerging role of RNA modification and long noncoding RNA interaction in cancer. Cancer Gene Ther 31:816–830

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Zhang Z (2020) The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 17:807–821

Zhang A, Miao K, Sun H, Deng C-X (2022) Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. Int J Biol Sci 18:3019–3033

Zhao X et al (2017) Cell cycle-dependent control of homologous recombination. ABBS 49:655–668

Article  CAS  PubMed  Google Scholar